key: cord-0924478-o1bti8x7
authors: Darbandi, Atieh; Asadi, Arezoo; Ghanavati, Roya; Afifirad, Roghayeh; Emamie, Amir Darb; kakanj, Maryam; Talebi, Malihe
title: The Effect of Probiotics on Respiratory Tract Infection with Special Emphasis on COVID-19: A Periodic Review during 2010-2020
date: 2021-02-09
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.02.011
sha: b2a4d74c37bda6e285d5e55b1cf385386bdf6eb9
doc_id: 924478
cord_uid: o1bti8x7

To evaluate the effects of probiotic on patient’s respiratory tract infection (RTI), a systematic review was conducted on randomized controlled trials (RCTs). PubMed, Google Scholar, Embase, Scopus, Clinicaltrials.gov, and International Clinical Trials Registry Platform (ICTRP) databases were systematically searched for the following keywords from January 2010 to January 2020: including respiratory tract infection, probiotics, viral infection, COVID-19, and clinical trial. A total of 27 clinical trials conducted on 9,433 patients with RTI and 10 ongoing clinical studies of probiotics intervention in COVID-19 were reviewed. In this systematic review, were attempted to study the potency of probiotics for the hindrance and/or treatment of RTI diseases extensively, which may be practical to conflict the new coronavirus (COVID-19). Overall, probiotics could significantly increase the plasma levels of cytokines, the effect of influenzae vaccine, and quality of life as well as reducing the titre of viruses and the incidence and duration of respiratory infections. These antiviral and immune-modulating activities and their ability to stimulate interferon production recommended that to use probiotics as adjunctive therapy to prevent COVID-19. The rapid spread of the virus has affected the entire world socially and economically. Given this extensive research on RCTs, were expected probiotics to be a rational complementary treatment for RTI disease and a viable option for faster recovery.

RTIs are the result of an imbalance in the microbial population of the respiratory tract and gastrointestinal tract, affecting the lungs mucosa (Kumar et al., 2018) . This dysbiosis may subsequently alter immune function and predispose to secondary bacterial infection (Getahun et al., 2010) . The gut microbiome has a critical impact on inducing immune responses at distant mucosal sites, including the lungs (Abt et al., 2012) . Studies have shown that administration of certain Bifidobacteria or lactobacillus has a beneficial impact on RTIs (Zelaya et al., 2016) .

For example, in a study, the frequency and severity of cold symptoms in patients with rhinovirus infection were shown to be lower in the L. rhamnosus (LGG) treated group than in the control group (Kumpu et al., 2015) . L. delbrueckii subsp. bulgaricus OLL1073R-1 (R-1) was also shown to augment NK cells activity and reduce common cold symptoms (Makino et al., 2010) . L. paracasei subsp. paracasei (L. casei 431) shortened the duration of upper respiratory infection symptoms (Nagai et al., 2011) . L. plantarum augmented the innate and acquired immune responses in mice and human and reduced RTIs in the treatment group compared to the control group (Merenstein et al., 2010) . Also, B. animalis subsp. lactis Bl-04 (Bl-04) was shown to decrease the risk of upper respiratory illness in the natural setting (Turner et al., 2017) .

Given the above explanations about the results of various studies on the use of probiotics, their use may also play a role in reducing the ARDS severity, as a major complication of COVID-19. The effects of probiotics against several coronavirus species have been reported in various studies, while none of these effects and mechanisms have yet been examined on the new SARS- CoV-2 (Din et al., 2020) .

Data show that SARS-CoV-2 in patients causes gastrointestinal complications, and probiotics appear to be able to reduce the dissemination of coronavirus via the gut, the probiotic strains

have not yet been administered to the respiratory tract (Seo et al., 2010) . Direct inhibition seems to be impossible at this site. It could be said that host-microbe, microbe-microbe, and immune-J o u r n a l P r e -p r o o f microbe interactions could influence the course of respiratory diseases (Gonzalez-Ochoa et al., 2017 ). An imbalance between anti-inflammatory and pro-inflammatory cytokines, leading to cytokine storm, eventually contribute to the development of COVID-19 (Rizzardini et al., 2012) . Also, some probiotic components could bind to spike proteins (S) and ACE2 receptor proteins and prevent the virus from entering the host body (Anwar et al., 2020) . Finally, according to what has been said, the use of probiotics could be effective in reducing respiratory infections as well as COVID-19.

This systematic review aimed to evaluate the outcomes of clinical trials assessing the efficacy of the probiotics in the treatment of respiratory infections over the past 10 years.

For this systematic review, the guidelines established by PRISMA were followed (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) (Moher et al., 2009 ).

The keywords including respiratory tract infection, probiotics, viral infection, and clinical trial were searched in PubMed, Google Scholar, Embase Scopus, Clinicaltrials.gov, and International Clinical Trials Registry Platform (ICTRP) databases. Papers published in English from January 2010 to January 2020 were further assessed based on their title, abstract, and main text to ensure their relevance to the present study. Data extraction was conducted by two independent researchers, and papers indexed in 2 or more databases were considered only once. References lists of all the related articles were investigated to identify any ignored articles. A third researcher checked the results to ensure that all the eligible articles were evaluated.

The extracted data were organized based on the name of authors, country, date of publication, type of clinical trial, size of the sample, diagnostic criteria, characteristics of patients, the period J o u r n a l P r e -p r o o f of study, genus and species of probiotics used, dose of probiotics used, side effects of probiotics, and outcomes of treatment. Chi-square test was used to analyse the qualitative variables. Data were analysed using SPSS software Version 24.0 (IBM, NY), and a p-value ≤ .05 was considered statistically significant.

The inclusion criteria for considering full-text publications were the following: (i) articles published during the last 10 years; (ii) clinical trial studies, and (iii) clinical trial studies conducted on patients with RTI.

The exclusion criteria were (i) animal experiments; (ii) congress papers; (iii) reviews, metaanalysis, case reports, letters to the editor, and correspondences; (iv) clinical feature summary;

(v) non-English articles; (vi) studies with no clear information.

[ Figure 1 near here]

A total of 1,268 articles were retrieved from the international databases of Google Scholar, Medline, Embase, and Scopus. Figure 1 shows a schematic representation of the search method used in this article. In the second phase, after removing duplicates, 77 studies remained, among which 50 articles were excluded based on their title and abstract, and 27 articles were selected for detailed full-text evaluation and further analysis the efficacy of the probiotics in the treatment of respiratory tract infections. The outcomes of different clinical trials assessing the efficacy of the probiotics in the treatment of respiratory tract infections are shown in Table 1 .

The largest number of studies in this field was related to studies conducted in Japan (7 out of 27 studies, and 3,293 out of 9,433 patients). In total, 73% of the patients surveyed were women, and 27% were men (Figure 2) with different age groups (infant-89 years). The specimens included blood, serum, and nasopharyngeal swab. Among the 27 clinical trials, 23 trials were conducted on the efficacy of the probiotics in the treatment of RTI, 1 trial was conducted on the synbiotics efficacy, and 2 trials were conducted on the prebiotics efficacy and 1 trial was conducted on the probiotic and prebiotic separately.

Among the 15 different probiotic strains studied in these 27 articles, Lactobacillus species were studied more than Bifidobacteria; also, L. paracasei and L. rhamnosus (15%) were identified as the most common probiotic strains used in these studies. The frequency of different types of probiotic species used in reviewed studies for patients with RTI is shown in Figure 3 . The prescribed doses of these strains were between 1×10 9 and 1×10 11 (average dose: 5.05×10 10 ) colony forming units (CFU) for 6 and 24 weeks.

Among the 27 clinical trials reviewed, 9 trials examined a combination of multi-strain probiotic bacteria and 15 studies examined mono-strain probiotic bacteria and as mentioned above 2 trials were conducted on the prebiotics efficacy and 1 trial was conducted on the probiotic and prebiotic cocktails. In 9 studies, a combination of two probiotic bacteria was used, while only in 2 studies, a combination of three probiotic bacteria was used. 

Of the 27 articles reviewed, 3 studies showed that probiotics did not play a significant role in boosting the immune system and improving the body's defences against diseases (Enani et al., 2018 , Rizzardini et al., 2012 .

In a study, the intake of probiotics was reported to increase the population of natural killer (NK) T cells compared to the control group (40.9 vs. 24.1) as well as the expression of the memory marker CD45R0 on the surface of CD8+ lymphocytes. The plasma levels of cytokines J o u r n a l P r e -p r o o f in various categories, anaphylatoxins, pro-inflammation, and other cases were also studied by researchers. The plasma concentrations of complement C4a and C5a, cytokines (interleukin-1β, IL-6, IL-8, IL-12, IL-5, and IL-10), and tumor necrosis factor α (TNF-α) were evaluated in the probiotic and control groups. In general, the level of cytokines was increased in the probiotic groups due to the use of probiotics. However, the IL-6 level in the probiotic groups was higher than in the control groups.

Of the 27 selected papers, 7 and 1 papers were conducted on the effects of probiotics and prebiotic compounds to improve vaccine performance. According to the review of these studies results, the effects of probiotics on the immune response to influenza vaccination are shown in Table 2 . People in these studies were distributed into the control and probiotic groups. The overall mean age of the patients was 59.7 years, ranging from 18 to 99 years; 60% of females and 40% of males completed the studies. The most common probiotic species studied was Lactobacillus, and only 2 study evaluated B. Longum, and 1 study evaluated a combination of Lactobacillus and Bifidobacterium.

On average, the probiotic groups consumed capsules containing 1×10 9 to 1 × 10 11 CFU of probiotic strains daily for 28 to 98 days. The vaccination was conducted by medical services with a vaccine containing inactivated trivalent (H1N1, H3N2, and B) influenza virus. The antibody titers against the three viral antigens included in the vaccine were evaluated at baseline and 2, 6, 8, and 10 weeks after influenza vaccination. Seroconversion was defined as the proportion of vaccinated individuals achieving a haemagglutination inhibition (HAI) titer of > 1:40 against at least one of the viral subtypes included in the vaccine. The present study results showed a significant increase in total plasma IgG titer in the probiotic groups compared to the control groups (14.27 and 10.67, respectively). The seroconversion against at least one J o u r n a l P r e -p r o o f of the antigens in the vaccine was 4.94 times higher in the probiotic groups than in the control groups.

Evaluation of the immune benefits of two probiotic strains of B. animalis subsp. lactis BB-12 and L. paracasei subsp. Paracasei, L. casei 431 in an influenza vaccination model indicated that an increase in specific IgG was greater in both probiotic groups vs. placebo (Rizzardini et al., 2012) .

[ Table 2 near here]

The evaluations performed in this study indicated that there was no significant difference between the two study groups (probiotic groups vs. control groups) in terms of the incidence of AEs. However, there were more gastrointestinal-related AEs in the placebo groups (41.8%) compared to the probiotic groups (32.25%). The most common gastrointestinal-related AEs in the placebo groups included nausea (16.74%), diarrhea (3.59%), vomiting (16.9%), abdominal pain (3.83%), and flatulence (3.62%), while in the probiotic groups, nausea (5.72%), diarrhea (7.93%), vomiting (3.9%), abdominal pain (2.85%), and flatulence (2.07%) were the most common AEs. Non-gastrointestinal adverse events including rhinorrhea, headache, cough, muscle aches, sore throat weakness, chills, and fever were lower in the probiotic groups (11.87%) compared to placebo (22.5%).

The review of faecal recovery results of various studies indicated that two important Lactobacillus species were significantly increased in the probiotic groups. A significant increase was reported in the number of L. plantarum (6.9×10 5 and 6.4 ×10 5 cells/g in the J o u r n a l P r e -p r o o f probiotic and control groups, respectively) and L. paracasei (from 9.7×10 4 to 1.4×10 6 and 1.8×10 6 cells/g in the probiotic and control groups, respectively) after 2 and 12 weeks.

In the reviewed studies, it was shown that Lactobacillus and Bifidobacterium count in the probiotic group increased (≥10-fold). While the Bacteroides count in the probiotic group after 8 weak was significantly lower than in the control group. Finally, according to the present study results, there was no significant difference in the count of Clostridium leptum, Enterobacteriaceae, and Enterococcus between the control and probiotic groups.

The present study results showed that the incidence, prevalence, and duration of respiratory infections symptoms were significantly lower in the probiotic groups, especially sore throat and cough. Finally, the incidence of local respiratory symptoms (sore throat, cough, and/or nasal congestion) was approximately 42% lower in the probiotic groups compared to the control groups (p =.007).

Subjects' QOL was assessed in different studies after the start of the intervention using interview and asking questions associated with lifestyle and health status. The questions covered the following items that were asked twice, once before the start and once after the end of the treatment courses: physical functioning, group performance, body pain, general health perception, vitality, social functioning, the role of emotion, and mental health. The postintervention score of the general health perception subscale in the probiotic groups was significantly improved compared with the control groups.

Of the 27 studies reviewed, 4 trials detected the effects of the probiotics on reducing viral load in the probiotic groups vs. the control groups. The immune response to viral infections was significantly increased in the probiotic treated groups. Probiotics also decreased viral titer in the respiratory system and the proportion of subjects shedding the virus in nasal secretions (56% in the probiotic groups, and 91% in the control groups).

In a trial by Lehtoranta et al., fewer viruses were detected in the probiotic group than in the control group, including picornavirus, influenza A and B viruses, respiratory syncytial viruses (RSV) (A and B), human parainfluenza viruses type 1 to 4 (HPIV1-HPIV4), adenovirus (AdV), and human metapneumovirus (hMPV). The number of picornaviruses (mainly RV) in the probiotic group was three times lower than in the control group (p = .0069) only in September (Lehtoranta et al., 2014) .

Many studies have shown the role of probiotics in reducing respiratory infections, but there are also some studies suggesting the opposite. For example, Gleeson et al. showed that the incidence of upper respiratory tract infection symptoms was unexpectedly low (mean 0.6 per individual), and there was no significant difference between the probiotic and placebo groups.

Also, the duration and severity of upper respiratory tract infection symptoms were not influenced by probiotic (Gleeson et al., 2012) . Turner et al. (2017) indicated that there was no significant difference between the probiotic (Bifidobacterium animalis subsp. lactis Bl-04) and placebo groups in terms of the serum level of CXCL10, IL-6, GCSF, CXCL8, IL-1β, and CCL2; decrease in viral titers (RV-A39); and shedding of virus in nasal secretions (p=.02) (no data) (Turner et al., 2017) .

J o u r n a l P r e -p r o o f Probiotics have been considered in clinical trials to reduce the clinical protests and severity of COVID-19. To the best of our knowledge, no published studies so far have reported the use of probiotics as a supportive treatment for the management of COVID-19.

Ten ongoing clinical studies of probiotics intervention in COVID-19 from January 2020 to January 2021 were founded. Some of these studies did not specify exactly the type of probiotic Table 3 summarises ongoing clinical studies of probiotic intervention in COVID-19.

[ Table 3 near here]

The previous studies have reported that the overall annual charge of non-influenza-related viral respiratory tract infections (VRTI) approaches about 40 billion $ (Gleeson et al., 2016) . One of the most important causes of respiratory infections is influenza, which is the principal leading cause of morbidity and mortality in the USA, leading to about 19000-36000 deaths and 200 000 surplus hospitalizations per year (Davidson et al., 2011 , Fiore et al., 2010 .

COVID-19 as a respiratory viral infection has swiftly extended into a global pandemic with remarkable health and economic burden. To date, there is no approved remedy or prophylactic remedial strategy for it. The overall cost of SARS-CoV-2 to the global economy has been estimated to be between US$30 billion and US$100 billion (Fendrick et al., 2003) . Treatment of this respiratory disease is often symptomatic, and oxygen therapy is the mainstay of treatment for patients with severe infections. In cases of oxygen-resistant respiratory failure, for controlling septic shock, mechanical ventilation may be necessary (Lythgoe and Middleton, 2020) .

Other treatments used so far including systemic corticosteroids not recommended for treatment of viral pneumonia or acute respiratory distress syndrome (ARDS). Also, various methods such as lopinavir / ritonavir (100/400 mg every 12 hours), Chloroquine (500 mg every 12 hours) and hydroxychloroquine (200 mg every 12 hours) have been suggested for treatment. Therefore, treatments reducing the period of infection, the rate of infection, the severity of symptoms, and J o u r n a l P r e -p r o o f the mortality rate are of chief interest both for the individuals and the entire society and treatment staff. Furthermore, unreflective or inappropriate administration of antibiotics should be avoided. However, in this scenario, professionals are proposing diverse alternative drugs like Ayurveda, Siddha, and herbal medicines and other related therapeutic approaches to control COVID-19 (Hu et al., 2020) .

This review study aimed to comprehensively evaluate the effectiveness of probiotics in the control, prevention, and/or treatment of viral infectious diseases, which may also be effective against the new viral infectious coronavirus disease. So far, most applications and studies on probiotics were confined to the gastrointestinal tract because of their significance and traditional use in this area. However, the use of probiotics in recent randomized clinical trials (RCTs) on respiratory tract infections has augmented because of their broad range of applications and their potential effectiveness in the control or therapy of some infections, including allergy and atopic dermatitis (Prince, 2020) . The review of the previous studies showed that probiotics impact on common upper respiratory tract infections or viral infections was widely evaluated in RCTs and resumed in numerous reviews and meta-analysis (King et al., 2014 , Prince, 2020 , Shin et al., 2015 . This systematic review aimed to evaluate the outcomes of clinical trials assessing the efficacy of the probiotic in RTI treatment over the past 10 years.

Of the 27 articles reviewed, 3 studies showed that probiotics did not play a significant role in boosting the immune system and improving the body's defences against diseases. The discrepancies in response to probiotic treatment in different studies might be due to the differences in the characteristics of the host (age, sex, and lifestyle), differences in URTI incidence, insufficient number of subjects, the season of study, the dose of regimens, duration J o u r n a l P r e -p r o o f of treatment, severity of the disease, the single or multi-strain formulation used, delivery modes, and so on, which require further detailed investigations.

The exact mechanisms of action of probiotics on RTI are not yet known. The action of probiotics seems to be distinctly related to probiotics specific species and strains. There seem to be several mechanisms in probiotics function, depending on the probiotic's specifications and target diseases. However, it seems that probiotics presumably have a similar effect in general. Many of the mechanisms of anti-inflammatory actions of probiotics in the gut system might be applied to the respiratory tract (Prince, 2020) . Inflammation plays a fundamental role in the pathogenesis of COVID-19; an imbalance between pro-inflammatory and antiinflammatory cytokines, resulting in a cytokine storm, is currently considered as a major factor in the expansion and development of COVID-19 (Hao et al., 2015) . Thus, the homeostatic balance between Treg (IL-10) and Th17 (IL-17) cells is disturbed in COVID-19. Intestinal epithelial cells (IECs) could secrete and reply to different cytokines via the presentation of CD1d, as an MHC-like molecule producing anti-inflammatory cytokine IL-10 since the activation of STAT3 (Hao et al., 2015) .

Dendritic cells (DCs), as a heterogeneous family of immune cells, are one of the key factors in regulating immune responses by linking innate and acquired immune responses through accurately recognizing pathogenic and endogenous inflammatory signals. They could be subdivided into plasmacytoid (pDCs), myeloid DCs (mDCs), and CD8 dendritic cells. Among which, pDCs are a rare and essential subset acting as a "control tower" in viral infections by producing a large quantity of IFNs (Lythgoe and Middleton, 2020) . In macrophage cell culture,

inducing type I interferon-related gene activation (Lythgoe and Middleton, 2020) . In some studies, the probiotic L. lactis JCM5805 has been reported to decrease common cold symptoms J o u r n a l P r e -p r o o f and activate human pDCs among PBMCs, especially in a subgroup of healthy candidates initially demonstrating low pDCs activity (Rizzardini et al., 2012) .

The role of pDCs and type 1 IFNs in viral and bacterial infections is complex; pDCs use specific TLRs to detect bacteria and viruses. Among TLRs, TLR9 diagnoses microbial nucleic acids through detecting unmethylated CpG motifs of DNA, and TLR7 recognizes microbial RNA or synthetic guanosine analogues. The activation of pDCs by TLR ligand binding contributes to the production of type 1 IFNs as the first-line defence against infection, which acts through blocking viral replication. The production of type 1 IFNs is often associated with viral infections, and it is well known that pathogenic bacteria stimulate IFN-α production.

However, non-pathogenic bacteria including probiotics used in food preparation have been less intensively studied regarding their potency to stimulate DC-mediated IFNs induction. In a study, various lactic acid bacteria were examined for their ability to stimulate pDCs-mediated IFN-α production, leading to the identification of L. lactis JCM 5805 probiotic as a strong stimulator of type 1 IFN production (Kawai and Akira, 2011 , Prince, 2020 , Swiecki and Colonna, 2015 . Several RCT studies have shown different effects of probiotic strains on different innate immune markers (Cox et al., 2010 , Olivares et al., 2007 , Rautava et al., 2006 , Schiffrin et al., 1995 . However, a typical viral infection challenge in the immune system increases the cascade of immune functions by increasing cytokines, natural killer activity, and phagocytosis in the early days of infection, which are gradually replaced by viral antigen-specific T cells responses (Burleson and Burleson, 2007, Calder, 2007) . The liberation of soluble agents by probiotics could increase the processes of immune cells or epithelial cells that subsequently affect immune cells. Also, probiotics could regulate the activity of the immune system near or far from the target organ (Darbandi et al., 2019 , Shin et al., 2015 .

Many clinical trials have shown that probiotics stimulate the antibody response to viral vaccination (Aubin et al., 2008 , Boge et al., 2009 , Davidson et al., 2011 , Namba et al., 2010 .

In this review, the most common probiotic species studied in vaccination was found to be J o u r n a l P r e -p r o o f after probiotic supplementation in this research suggests that the activities of both T-helper (Th)1 and Th2 lymphocytes are boosted, as IgG1 and IgG3 are considered to be more representative of Th2 and Th1 responses, respectively. In addition to being preferentially associated with Th1 and Th2 T-cell subsets, IgG1 and IgG3 are also correlated with optimal activation of supplement and phagocytosis by macrophages, respectively (Rizzardini et al., 2012) .

Lactobacillus strains in the prevention of influenza infection. In a study on a mouse model of H1N1 influenza infection, intranasal disposal to LGG for 3 days was significantly associated with a lower frequency of accumulated symptoms and also a higher survival rate compared to control mice . In another study on the same mouse model of influenza infection, oral administration of LGG or Lactobacillus TMC0356 for 19 days resulted in lower clinical symptom scores and pulmonary viral titters in comparison with control mice .

Based on the safety measures of the Advisory Committee, the annual influenza vaccination is currently recommended for all adults and children over 6 months (Fiore et al., 2010) . Although the highest morbidity and mortality rates are among young children and the elderly, studies have shown that influenza vaccination in healthy adults reduces both direct and indirect medical costs, such as visiting a doctor, preventing co-infections with bacteria and viruses, and using antibiotics. Therefore, probiotic use is recommended to further increase immunization of vaccination (Nichol et al., 1999 , Wilde et al., 1999 . A Study of North Carolina State University on Coronavirus disease shows the technology that using L. acidophilus probiotics expressing SARS-CoV-2 proteins as potent vaccines (Fendrick et al., 2003) .

The discussion over the superiority of different species/strains of probiotics is very complex.

Because of the strain-specific abilities of probiotics and the existence of different categories of J o u r n a l P r e -p r o o f patients, a specific probiotic might not be suitable for all patients (Zocco et al., 2006) . Most probiotic products include species of Lactobacillus and Bifidobacterium genera, which modulate the gut microbial population and enhance intestinal barrier function (Kleerebezem and Vaughan, 2009, Li et al., 2016) . It is believed that probiotics could modulate intestinal microbiota and stabilize the beneficial microbial population by competing with pathogenic bacteria for nutrients and adhesion sites and producing various metabolites. Yoshimatsu et al. showed that probiotic therapy was most beneficial for patients who initially had cluster-Ⅰ microflora rather than cluster-Ⅱ flora (Yoshimatsu et al., 2015) . In a study, the effects of LGG on the prevention of experimental rhinovirus infections in healthy volunteers were investigated.

The severity of cold symptoms and the frequency and number of patients with rhinovirus infection in the LGG group were lower than in the control group, although there was no significant difference between the study groups (Kumpu et al., 2015 , Van Puyenbroeck et al., 2012 . Other studies from Duke University are processing prescripts to research hindrance and remedy of SARS-CoV-2 in an extent of at-danger groups in eluding initial multicentre, RCT, placebo-controlled phase 2 trial will measure if the probiotic L. rhamnosus GG has a function in hindrance and cure of COVID-19 infection. In another study, the children with cryptosporidium diarrhea infection were given LGG, showing a significant improvement in intestinal permeability. The exact mechanism of action of probiotics on the immune system is not fully understood. However, LGG has been shown to modulate innate and adaptive immune responses by increasing serum IgG and IgA levels and targeting intestinal pathogens such as rotavirus (Kumpu et al., 2015 , Prince, 2020 .

Although most studies on microbiota in the human body have been conducted on the human intestinal tracts, those on the respiratory tract microbiota are expanding and advancing owing to novel biotechnologies (Gollwitzer and Marsland, 2014) . Even today, it is hard to assure that respiratory microbiota constituents and acts are analogous to those of the intestinal microbiota J o u r n a l P r e -p r o o f in expanding and protecting immune activities of the lung. There are augmenting shreds of evidence suggesting that there are relationships between the respiratory microbiota and many lung diseases and that microbial changes in the respiratory microbiota could cause illness in a human. Thus, it could be suggested that probiotic bacteria potentially control the intestinal inflammatory responses by confirming the gut mucosal barrier and the microbial environment as well as by degrading enteral antigens and changing their immunogenicity (Darbandi et al., 2019) . The results of other study showed that inter-personal diversity in gut microbiome will affect the officiousness of suggested microbiota interventions for SARS-CoV-2 infection.

Since the onset of COVID-19 disease, different antiviral drugs have been studied to treat the SARS-CoV-2 virus, and finally, on May 1, 2020, an antiviral drug called Remdesivir became the first FDA-approved emergency drug to treat COVID-19 (Grein et al., 2020) . Although the results of the observations do not provide any direct evidence of interaction of the intestinal microbiome with Remdesivir, some observe that there is a history of modification of the intestinal microbiome of other antiviral drugs (Domínguez-Díaz et al., 2019) .

No published studies so far have reported the use of probiotics as a supportive treatment for the management of COVID-19 (Table. 3). However, the International Scientific Association of Probiotics and Prebiotics (IASPP) has highlighted that scientists and clinicians globally are investigating the relationship between the gut microbiome and susceptibility to COVID-19 and assessing the role of various probiotics strains to lower viral load via different mechanisms (Hu et al., 2020) .

Most of the properties of probiotics are strain-specific, and multi-species probiotics may be more efficient than mono-species probiotics in the treatment of certain clinical conditions; for example, Rerksuppaphol et al. reported that administration of a two-strain probiotic combination (L. acidophilus 10 9 / capsule and B. bifidum 10 9 / capsule) to school children aged 8-13 years twice daily for 3 months during winter resulted in a significant decrease in J o u r n a l P r e -p r o o f respiratory symptoms including fever and cough as well as the length of absenteeism from school compared to placebo (Rerksuppaphol and Rerksuppaphol, 2012) . Although there are conflicting data regarding the effects of probiotics on RTI treatment (Jespersen et al., 2015 , Kinoshita et al., 2019 , Kumpu et al., 2015 , 8 extensive studies reviewed in the current research showed that the probiotic cocktail VSL#3 could successfully induce RTI remission among patients.

The results of many studies suggest that probiotics as health supplements and treatment agents are safe (Ahrén et al., 2021) . However, the side effects of probiotics should be controlled when used in a specific population. According to the literature search, 2 trials showed the side effects of probiotic consumption. Ahrén et al. reported that there was no significant difference between the study groups regarding the incidence and the overall number of side effects reported by children. However, more gastrointestinal side effects in the probiotic group compared to the placebo group seem to be explained by a higher frequency of vomiting, an adverse event was also reported in other studies following the administration of probiotics to young children (Ahrén et al., 2021) .

So far, drugs are being tested with no apparent success as yet, we have well-advised probiotics in clinical trials to decrease the load and severity of this disease. The result of ongoing studies in different countries has shown whether probiotic strains, especially lactobacilli, in the respiratory tract can decrease viral activity through multifactorial function, barrier and antiinflammatory, in the risk of secondary bacterial infections between Covid-19 patients.

Scientists are also working the special strains of lactobacilli with immunostimulatory events to support the intranasal SARS-CoV-2 immunization or the potentiality of a genetic technologist antigen-producing organism for vaccine transfer. Another RCT study showed the role of the gut microbiota as a prime play in rendering a good antibody response against influenza, which exhibited that gut microbiota could change the response for vaccines (Hagan et al., 2019) .

Many studies have shown that a mixture of probiotics or prebiotic-synbiotic combinations could improve RTIs and clinical symptoms in treated patients in all age groups. For example, a clinical study by Sazawal et al. on 1 to 4 year-old children reported the beneficial effect of adding prebiotics oligosaccharide and B. lactis HN019 to milk in preventing and controlling severe respiratory infections and preventing diarrhea in this group (Sazawal et al., 2010) .

Similarly, an RCT study showed that consumption of a probiotics-containing dairy drink was able to reduce the occurrence of dysentery episodes by 21% (95%CI: 0-38%; p = .05), pneumonia by 24% (95%CI: 0-42%; p = .05), severe acute lower respiratory infection by 35% (95%CI: 0-58%; p = .05); and the duration of disease severity and high fever by 16% (95%CI: 5-26%, p = .004) and 5% (95%CI: 0-10%; p = .05), respectively (Guillemard et al., 2010 , Makino et al., 2010 .

According to experiments performed, the optimal combination and dose of probiotics for the treatment of original diseases have not yet been determined. However, it is commonly avowed that 10 8 -10 9 CFU/g of probiotic should be used daily to deliver a minimum concentration of 10 6 viable cells into the intestine to exert positive effects on host (Knorr, 1998 , Neffe-Skocińska et al., 2018 . In original trials assessed in this review, probiotics were administered at doses between 1×10 9 to 1×10 11 CFU for 6 and 12 weeks. Overall, according to the treatment results of patients with RTI, the best-recommended dose was 5.05×10 10 CFU/g an average, showing good efficacy in reducing respiratory symptoms, reducing the duration of the disease, and increasing immunity. Some studies have shown that a probiotic dose higher or lower than 5.05×10 10 CFU/g is only effective in increasing QOL and response to general symptoms (Lorenzo-Zúñiga et al., 2014) . Also, not all the probiotics effects on human health seem to be related to the viability of bacteria since even heat-killed probiotic bacteria or probiotic-derived J o u r n a l P r e -p r o o f DNA was shown to have the potency to improve significant health problems (Arimori et al., 2012 , Hirose et al., 2006 , Merenstein et al., 2010 .

We could conclude it from the literature review that the benefit of probiotics and synbiotics as prophylaxis and complementary in patients with RTI is a promising preventive strategy to reduce the severity of respiratory infection symptoms, reduce the duration of disease, improve individual's quality of life, and induce and maintain remission in patients with RTI. The therapeutic strategies such as the optimal dose, consumption duration time, and it has not yet agreed on the species of probiotics upon.

As a result, this systematic review show, a broad clinical-base studies with attentive multicentre activities from different countries RCT studies which will progress our cognition to coming up the potential probiotic and/or prebiotic, symbiotic of microbiota and dietary use as an alternative administration choice for SARS-CoV-2. The proportion of subjects who contracted influenza was significantly lower in BB536 group than in the to placebo group. The proportion of subjects with fever was also significantly lower in the BB536 group than in the placebo group. In the BB536 group, the NK cell activity and the bactericidal activity of the neutrophils were significantly higher at week 5 than to before BB536 administration. 

Commensal bacteria calibrate the activation threshold of innate antiviral immunity

Fewer Community-Acquired Colds with Daily Consumption of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700: 2. A Randomized, Placebo-Controlled Clinical Trial

Enhanced vaccination effect against influenza by prebiotics in elderly patients receiving enteral nutrition

Antiviral effects of probiotic metabolites on COVID-19

Daily intake of heat-killed Lactobacillus plantarum L-137 enhances type I interferon production in healthy humans and pigs

A probiotic fermented dairy product improves immune response to influenza vaccination in the elderly

New treatments for influenza

Randomised, double-blind and placebocontrolled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections

A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials

Immunological parameters: what do they mean?

Topographical continuity of bacterial populations in the healthy human respiratory tract

Lactobacillus plantarum DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: A randomized, double-blind, placebo-controlled study

Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes

The effects of probiotics on reducing the colorectal cancer surgery complications: A periodic review during

Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized doubleblind placebo-controlled trial

Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind ,randomized, controlled trial

Microbiota and its role on viral evasion: is it with us or against us?

Applying psychological theories to evidence-based clinical practice: Identifying factors predictive of managing upper respiratory tract infections without antibiotics

Effects of Lactobacillus coryniformis K8 CECT571 on the immune response to influenza vaccination and the assessment of common respiratory symptoms in elderly subjects: a randomized controlled trial

HIV infection-associated tuberculosis: the epidemiology and the response

Effects of a Lactobacillus salivarius probiotic intervention on infection, cold symptom duration and severity, and mucosal immunity in endurance athletes

Effects of Lactobacillus casei Shirota ingestion on common cold infection and herpes virus antibodies in endurance athletes: a placebocontrolled, randomized trial

Modulation of rotavirus severe gastroenteritis by the combination of probiotics and prebiotics

Compassionate use of remdesivir for patients with severe Covid-19

Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial

Antibioticsdriven gut microbiome perturbation alters immunity to vaccines in humans

Probiotics for preventing acute upper respiratory tract infections

Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responses

Daily intake of heat-killed Lactobacillus plantarum L-137 augments acquired immunity in healthy adults

Probiotics, prebiotics and dietary approaches during COVID-19 pandemic

Galactooligosaccharide supplementation reduces stress-induced gastrointestinal dysfunction and days of cold or flu: a randomized, double-blind, controlled trial in healthy university students

Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion

Effect of Lactobacillus paracasei subsp. paracasei, L. casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunteers: a randomized, double-blind, placebo-controlled, parallel-group study

Toll-like receptors and their crosstalk with other innate receptors in infection and immunity

Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infection

Probiotics as an alternative strategy for prevention and treatment of human diseases: a review

Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis

Probiotic and gut lactobacilli and bifidobacteria: molecular approaches to study diversity and activity

Technology aspects related to microorganisms in functional foods

Effect of live and inactivated Lactobacillus rhamnosus GG on experimentally induced rhinovirus colds: randomised, double blind, placebo-controlled pilot trial

Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, doubleblind, placebo-controlled study

Specific probiotics and virological findings in symptomatic conscripts attending military service in Finland

Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice

31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life

Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial

Ongoing clinical trials for the management of the COVID-19 pandemic

Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1

The effects of nonviable Lactobacillus on immune function in the elderly: a randomised, double-blind, placebocontrolled study

Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Effects of oral administration of yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 and its exopolysaccharides against influenza virus infection in mice

Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cellmediated immunity in the elderly

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination

A comprehensive review of probiotics and their uses for control of viral infections in the wake of pandemic COVID-19

Specific probiotics in enhancing maturation of IgA responses in formula-fed infants

Randomized controlled trial of probiotics to reduce common cold in schoolchildren

Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study

Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial

Putative probiotic Lactobacillus spp. from porcine gastrointestinal tract inhibit transmissible gastroenteritis coronavirus and enteric bacterial pathogens

Progressive myoclonus epilepsy of Lafora

Probiotics used for respiratory diseases

Immunoprotective effects of oral intake of heat-killed Lactobacillus pentosus strain b240 in elderly adults: a randomised, double-blind, placebo-controlled trial

Effects of oral intake of plasmacytoid dendritic cells-stimulative lactic acid bacterial strain on pathogenesis of influenza-like illness and immunological response to influenza virus

The multifaceted biology of plasmacytoid dendritic cells

Efficacy of daily intake of Lactobacillus casei Shirota on respiratory symptoms and influenza vaccination immune response: a randomized, double-blind, placebo-controlled trial in healthy elderly nursing home residents

Effects of probiotic Lactobacillus brevis KB 290 on incidence of influenza infection among schoolchildren: an open-label pilot study

Probiotics to prevent respiratory infections in nursing homes: a pilot randomized controlled trial

Prevention and treatment of viral respiratory infections by traditional Chinese herbs

Effectiveness of influenza vaccine in health care professionals: a randomized trial

Respiratory antiviral immunity and immunobiotics: beneficial effects on inflammation-coagulation interaction during influenza virus infection

Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis

IgA (mg/dL

IgA (mg/dL

Higher H3N2-specific IgG levels were observed 3 w after vaccination

The authors report no conflict of interest.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The ethical committee of Iran University of Medical Sciences provided and endorsed the ethical approval for this study (IR.IUMS.REC.1399.1046).J o u r n a l P r e -p r o o f